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ABSTRACT
Dual-energy X-ray absorptiometric bone mineral density (DXA BMD) is a strong predictor of fracture risk in untreated patients. However,
previous patient-level studies suggest that BMD changes explain little of the fracture risk reduction observed with osteoporosis
treatment. We investigated the relevance of DXA BMD changes as a predictor for fracture risk reduction using data from the FREEDOM
trial, which randomly assigned placebo or denosumab 60mg every 6months to 7808 women aged 60 to 90 years with a spine or total hip
BMD T-score<2.5 and not<4.0. We took a standard approach to estimate the percent of treatment effect explained using percent
changes in BMD at a single visit (months 12, 24, or 36). We also applied a novel approach using estimated percent changes in BMD from
baseline at the time of fracture occurrence (time-dependent models). Denosumab significantly increased total hip BMD by 3.2%, 4.4%,
and 5.0% at 12, 24, and 36 months, respectively. Denosumab decreased the risk of new vertebral fractures by 68% (p< 0.0001) and
nonvertebral fracture by 20% (p¼ 0.01) over 36 months. Regardless of the method used, the change in total hip BMD explained a
considerable proportion of the effect of denosumab in reducing new or worsening vertebral fracture risk (35% [95% confidence interval
(CI): 20%–61%] and 51% [95% CI: 39%–66%] accounted for by percent change at month 36 and change in time-dependent BMD,
respectively) and explained a considerable amount of the reduction in nonvertebral fracture risk (87% [95% CI: 35% – >100%] and 72%
[95% CI: 24% –>100%], respectively). Previous patient-level studies may have underestimated the strength of the relationship between
BMD change and the effect of treatment on fracture risk or this relationship may be unique to denosumab. 2012 American Society for
Bone and Mineral Research.
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Introduction
Fractures are the main complication of osteoporosis and thegoal of therapy is to reduce fracture risk. Bone mineral
density (BMD) as assessed by dual energy x-ray absorptiometry
(DXA) remains the most widely utilized measure to identify
patients at risk for fracture. Epidemiological evidence demon-
strates a strong relationship between decreases in BMD and
increases in fracture risk.(1) However, the relationship between
gains in BMD and reduction in fracture risk in response to
therapeutic intervention remains a topic of investigation. The
relationship between treatment-induced BMD changes and
fracture risk reduction has been reported based on individual
patient-level clinical trial data,(2–10) and on summary statistics
from clinical trials using meta-analysis techniques.(5,11–13) At the
study level, a robust relationship has been suggested. However,
at the individual patient level, BMD changes with existing
therapies appear to account for little of the fracture risk reduction
observed, suggesting that BMD, although a strong predictor of
fracture risk in untreated patients, is not a strong predictor for
effects of osteoporosis treatments on fracture risk. These
observations have brought into question the utility of serial
BMD measurements to assess the effectiveness of osteoporosis
therapy.(14)
Denosumab (ProliaTM) is a fully human monoclonal antibody
against RANKL, a cytokine that is essential for the formation,
function, and survival of osteoclasts.(15,16) It has been approved
for the treatment of postmenopausal women with osteoporosis
at increased risk for fracture. Denosumab results in a rapid and
marked reduction in bone resorption, increases in BMD in the
trabecular and cortical compartments, and significant reductions
in fracture risk.(17,18) Denosumab results in an effect on BMD that
is larger than that of the bisphosphonate alendronate.(19–22) Of
particular note is the positive impact of denosumab on the
cortical skeleton.(21,23)
In the FREEDOM trial, denosumab reduced the risk of
new vertebral, hip, and nonvertebral fracture by 68%
(p< 0.001), 40% (p¼ 0.04), and 20% (p¼ 0.01), respectively.(17)
Our goal was to estimate the proportion of the reduction in
the risk of new or worsening vertebral and nonvertebral
fracture with denosumab treatment that would be accounted
for by changes in total hip BMD (percent of treatment effect
explained). Both a standard analysis, based on BMD change at a
fixed time point, and a more novel, time-dependent analysis
were used.
Methods
Study design and subjects
The design of the FREEDOM trial has been reported previously(17)
and is summarized here. FREEDOM was a multinational,
randomized, double-blind trial conducted at 214 centers in
postmenopausal women (N¼ 7808) with a BMD T-score< –2.5 at
the lumbar spine or total hip and not< –4.0 at either site.
Subjects received either 60mg denosumab or placebo subcuta-
neously every 6 months, and all subjects received daily
supplements of calcium (1000mg) and vitamin D (400 IU).
Measurements
Yearly hip DXA BMD measurements were obtained for all
subjects. New or worsening vertebral fractures were radiograph-
ically assessed at 12, 24, and 36 months per protocol.
Additionally, if a subject presented with back pain suggestive
of a vertebral fracture, an unscheduled X-ray was obtained and
used to confirm a new or worsening vertebral fracture.
Nonvertebral fractures were confirmed by imaging. All non-
vertebral fractures with the exception of those of the skull, face,
mandible, metacarpals, fingers, or toes were included in the
analysis. Pathologic fractures and severe trauma fractures were
not included. BMD and fracture assessments were performed by
a central reader (Synarc, San Francisco, CA, USA) blinded to
treatment assignment. This central vendor ensured quality
control across centers and longitudinally on study.
Statistical analyses
Historically,(2–6,8,10,24) the endpoint BMD (eg, BMD change at 12
or 36 months) has been used as the measure of BMD change
when describing the relationship between change in BMD on
therapy and fracture risk. In this traditional approach, the
endpoint BMD change utilizes the BMD change at a fixed time
point during the trial, even when the fracture may have occurred
years before the BMD was measured (eg, the percent change in
BMD being measured at 36 months and a fracture occurring
1 month after initiating therapy). To quantify the relationship
between BMD and new or worsening vertebral fracture, a logistic
regression model was used with new or worsening vertebral
fracture during the study as the response, and randomized
treatment and total hip BMD percent change from baseline at
endpoint as covariates. Separate models were fitted for percent
changes at 12, 24, and 36 months. When a BMDmeasure was not
available at the time point of interest, the last available BMD
measure (last observation carried forward) before that time point
was used. Similar methods were employed for nonvertebral
fracture using Cox’s proportional hazards model.
In addition to this traditional approach, we explored the
relationship when BMD was represented in a time-dependent
manner. For the assessment of new or worsening vertebral
fractures, a repeated-measure logistic regression was performed
with treatment as a fixed effect and the BMD percent change
from baseline as a time-dependent covariate. The annual BMD
value (months 12, 24, and 36) was used with the corresponding
annual vertebral fracture assessment. This analysis used new or
worsening vertebral fractures and allowed for a subject to have a
fracture at multiple time points.
When examining the relationship between time-dependent
BMD changes and nonvertebral fractures, a repeated-measures
model(25) was used to estimate individual BMD on the actual
BMD (g/cm2) scale at each unique nonvertebral fracture time. To
accommodate expected nonlinearity in BMD changes, quadratic
trajectories were fitted, with corresponding subject-specific
random linear and quadratic coefficients, as well as random
intercept. These estimates were converted to percent change
from baseline, which was used to represent the specific total hip
BMD at which each subject was at risk at the time of each
fracture. Cox’s proportional hazards model was then fitted with
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time-to-nonvertebral fracture as the response and randomized
treatment and total hip time-dependent BMD percent change
as covariates. Time-dependent BMD was treated as a time-
dependent variable.(26)
For all models, the interaction between BMD changes and
treatment was assessed. If the interaction was not significant at
the 10% level, summaries of the model excluded the interaction
term. A potential nonlinear relationship between fracture risk
and change in BMD was explored through restricted cubic
splines(27) and/or quadratic polynomials.
The percent of treatment effect explained was used to help
quantify these relationships, using Li’s method(6) for the point
estimate and the delta method to estimate the confidence
interval.(28) The percent of treatment effect explained provides a
measure for the extent to which the changes in BMD explain the
observed reduction in fracture. If the percent of treatment effect
explained is 100%, this indicates that all of the fracture risk
reduction is explained through the change in BMD. Li’s method
does not guarantee that the point estimate and confidence
interval for the percent of treatment effect are between 0% and
100%. The method involves fitting a statistical model that
includes both the percent change in BMD and the treatment
effect. The confidence interval will exceed 100% if the treatment
effect in this model is not statistically significant. This can happen
if the effect of treatment after adjusting for BMD changes is very
small or nonexistent; or when there is a substantial treatment
effect after adjusting for BMD changes, but the estimate of the
treatment effect has low precision.
Results
Baseline characteristics
The baseline characteristics of the 7808 women randomized in
the FREEDOM trial have been previously reported.(17) Table 1
lists the relevant baseline characteristics for the current analysis.
Age, total hip, and lumbar spine BMD T-score, prevalent vertebral
fractures, and history of nonvertebral fracture were similar
between the placebo and denosumab groups.
Effect of denosumab on BMD and fractures at 12, 24,
and 36 months
In the primary analysis of the FREEDOM trial, denosumab was
associated with higher BMD changes at the total hip at each
annual BMD assessment (Table 2). Additionally, denosumab
significantly reduced the risk of new vertebral fractures at
each annual assessment and of nonvertebral fractures at 24 and
36 months.
Relationship between change in total hip BMD and new
or worsening vertebral fracture efficacy
The analysis of the relationship between on-study changes in
BMD and fracture efficacy required both a baseline and at least
one postbaseline BMD measurement. Additionally, the new or
worsening vertebral fracture outcome required at least one
postbaseline radiograph. There were 7195 subjects in FREEDOM
(3590 placebo, 3605 denosumab) who had a baseline and at least
one postbaseline total hip BMD and vertebral X-ray assessment.
Of these, 339 subjects (258 placebo, 81 denosumab) experienced
a new or worsening vertebral fracture on study.
Figure 1 represents the relationship between percent change
in total hip endpoint BMD at month 36 and new or worsening
vertebral fracture risk. For both denosumab and placebo, the risk
of fracture decreased with increasing percent change in total hip
BMD but the slope of the curves differed between treatment
groups (interaction p value¼ 0.0003). This relationship was
further quantified through the percent of treatment effect
explained. The percent change at month 36 in total hip endpoint
BMD explained 35% (95% confidence interval [CI]: 20%–61%) of
the treatment effect (Table 3). For the placebo and denosumab
groups, each 1% increase in total hip BMD corresponded to a
4.9% and 13.5% reduction in new or worsening vertebral fracture
risk, respectively.
Assessment of the relationship between time-dependent BMD
changes and new or worsening vertebral fractures also showed a
decreasing risk of fracture with increasing BMD gains. Compared
with no change from baseline, subjects with increased BMD had
a lower risk of fracture and those with decreased BMD had a
higher risk. The change in total hip time-dependent BMD
explained 51% (95% CI: 39%–66%) of the new or worsening
vertebral fracture risk reduction (Table 3). For the placebo and
denosumab groups, each 1% increase in total hip BMD
corresponded to a 9.4% and 14.5% reduction in new or
worsening vertebral fracture risk, respectively.
Relationship between change in total hip BMD and
nonvertebral fracture efficacy
There were 7232 subjects in FREEDOM (3608 placebo, 3624
denosumab) who had a baseline and at least one postbaseline
BMD assessment. Of these, 500 subjects (278 placebo, 222
denosumab) experienced a nonvertebral fracture on study.
Figure 2 represents the relationship between percent change
in total hip BMD at month 36 and the incidence of nonvertebral
fractures. For both denosumab and placebo, the risk of fracture
decreased with increasing percent change in total hip BMD. The
data suggest similar relationships (slopes) for both treatment
Table 1. Baseline Characteristics
Placebo (N¼ 3906) Denosumab (N¼ 3902)
Age (years), mean SD 72.3 5.2 72.3 5.2
Total hip BMD T-score, mean SD –1.91 0.81 –1.89 0.81
Lumbar spine BMD T-score, mean SD –2.84 0.69 –2.82 0.70
Prevalent vertebral fracture, % (n) 23.4% (915) 23.8% (929)
History of nonvertebral fracture in those 55 years, % (n) 30.1% (1177) 29.8% (1163)
History of nonvertebral fracture, % (n) 38.6% (1507) 39.1% (1524)
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groups (interaction p value¼ 0.38). After accounting for the
effect of the percent change in total hip BMD, the treatment
effect was no longer significant (p value¼ 0.97). The change in
total hip BMD at month 36 explained 87% (95% CI: 35% to
>100%) of the treatment effect (Table 3). A 1% change in total
hip BMD at 36 months corresponded to a 3% change in
nonvertebral fracture risk regardless of treatment. The majority
of denosumab-treated patients showed positive changes and
the majority of placebo-treated patients showed negative
changes in total hip BMD.
Assessment of the relationship between time-dependent BMD
changes and nonvertebral fractures also showed a decreasing
risk of fracture with increasing BMD changes. Compared with no
change from baseline, subjects with BMD gains had a lower risk
of fracture and those with BMD losses had a higher risk. The
change in total hip time-dependent BMD explained 72% (95% CI:
24% to >100%) of the treatment effect (Table 3). A 1% total hip
BMD increase corresponded to a 4.5% reduction in nonvertebral
fracture risk.
Discussion
A strong relationship between DXA BMD and fracture risk has
been demonstrated by a number of epidemiological studies.(1)
However, the relationship between increases in BMD and
reduction in fracture risk as a result of therapeutic intervention
Table 2. Denosumab Treatment Effect on Total Hip BMD, and New or Worsening Vertebral and Nonvertebral Fracture Risk at 12, 24, and
36 Months
BMD Fracture
Mean (CI)
Difference
Mean (CI)
New or worsening
vertebral na
New or worsening
vertebral RR (CI)
Nonvertebral
nb
Nonvertebral
HR (CI)
Month 12
Placebo 0.0 (0.1, 0.1) 3.3 (3.1, 3.4) 82 0.39 (0.26, 0.58) 117 0.84 (0.65, 1.11)
Denosumab 3.2 (3.1, 3.3) 32 99
Month 24
Placebo 0.7 (0.8, 0.6) 5.1 (4.9, 5.2) 183 0.29 (0.21, 0.39) 214 0.79 (0.64, 0.96)
Denosumab 4.4 (4.3, 4.5) 53 170
Month 36
Placebo 1.4 (1.5, 1.3) 6.4 (6.2, 6.6) 264 0.32 (0.26, 0.41) 293 0.80 (0.67, 0.95)
Denosumab 5.0 (4.9, 5.1) 86 238
n¼ number of subjects with 1 fracture; CI¼ 95% confidence interval; RR¼ risk ratio; HR¼ hazard ratio.
aThere were 3691 women in the placebo group and 3702 in the denosumab group who were evaluable for new or worsening vertebral fractures.
bThere were 3906 women in the placebo group and and 3902 women in the denosumab group who were evaluable for nonvertebral fractures.
Difference and ratios reference placebo.
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Fig. 1. Relationship between new or worsening vertebral fracture inci-
dence at 36 months and percent change from baseline in total hip BMD
at 36 months. Adjusted estimates for a baseline lumbar spine BMD T-
score of2.5. Data represent the 5th through the 95th percentiles of total
hip BMD percent change. The density curves at the bottom represent the
distributions of total hip BMD change at 36 months for each treatment
group. For both denosumab and placebo, the risk of new or worsening
vertebral fracture decreased with increasing percent change in total hip
BMD but the slope of the curves differed between treatment groups
(interaction p value¼ 0.0003).
Table 3. Summary of Percent of Treatment Effect Explained
Timing of BMD
Percent of treatment effect explained
New or
worsening vertebral Nonvertebral
12 months 23 (13, 40) 35 (9, >100a)
24 months 30 (16, 54) 89 (37, >100a)
36 months 35 (20, 61) 87 (35, >100a)
Time-dependent 51 (39, 66) 72 (24, >100a)
Values are % (95% confidence interval).
aLi’s method allows for estimates of percent of treatment effect
explained that exceed 100%. Estimates were truncated at 100%.
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is less well established. Our analyses showed that with
denosumab treatment, larger increases in total hip DXA BMD
were related to greater reductions in new or worsening vertebral
and nonvertebral fracture risk. Regardless of the methodology
used (fixed time point or time-dependent models), the change
in total hip BMD may explain a considerable proportion (35%–
51%) of the effect of denosumab on risk reduction of new or
worsening vertebral fractures and appears to explain a
considerable amount of the reduction in risk of nonvertebral
fracture (80%).
The relationship between BMD change and fracture risk effect
in women treated for osteoporosis has been the subject of
previous reports. At the study level, a robust relationship has
been suggested. However, at the patient level, the relationship
has shown limited contributions of the BMD change to the
reduction in fracture risk. Hochberg et al.(24) showed that larger
increases in total hip and/or spine BMD while on alendronate
therapy were associated with lower risk of new vertebral
fractures. Cummings et al.(5) reported that in women with a
prevalent vertebral fracture, larger increases in spine BMD at
12 months were associated with lower fracture risk with
alendronate; however, BMD changes only accounted for 16%
(95% CI: 11%–27%) of the new vertebral fracture risk reduction. Li
et al.(6) showed that the BMD changes with 5.0mg daily
risedronate from the VERT-NA and VERT-MN trials accounted for
28% (95% CI: 16%–49%) of the fracture risk reduction.
Additionally, Li et al.(6) showed that the treatment effect was
still significant at the 5% level after adjusting for the BMD
changes. Watts et al.(9) combined the VERT-NA, VERT-MN, and
HIP trials to report that for risedronate, positive changes in
lumbar spine and femoral neck BMD over 3 years were similar
with respect to fracture reduction regardless of magnitude, and
changes in BMD explained only 18% (95% CI: 10%–26%) or 11%
(95% CI: 7%–15%) of vertebral fracture efficacy, respectively. In a
separate study, Watts et al.(10) showed for risedronate that 3-year
changes in lumbar spine and femoral neck BMD explained only
12% (95% CI: 2%–21%) and 7% (95% CI: 2%–13%), respectively,
of nonvertebral fracture efficacy. Wasnich et al.(8) showed that for
ibandronate, total hip BMD change at year 3 was a significant
predictor of vertebral fracture risk reduction, reporting that a 1%
increase in total hip BMD accounted for a 7.9% (p¼ 0.0084)
reduction in risk. Sarkar et al.(7) reported that femoral neck BMD
changes at 1 and 3 years were related to the risk of new vertebral
fracture for both raloxifene and placebo; however, a significant
treatment effect remained after adjusting for BMD changes.
Changes in femoral neck BMD at 3 years accounted for only 4%
of the vertebral fracture risk reduction. Changes in lumbar spine
BMD at 3 years was not associated with new vertebral fracture
risk in the raloxifene group, but was negatively correlated with
fracture risk in the placebo group.
The relationship, including slopes and intercepts, between
total hip BMD and nonvertebral fracture risk in the current study
was similar for those patients on placebo, most of whom lost
BMD, and those treated with denosumab, most of whom gained
BMD during the 3-year FREEDOM trial (Fig. 2). Because DXA BMD
assessment is influenced by (but does not distinguish between)
bone geometry and mineral content of the trabecular and
cortical compartments, it can be hypothesized that therapies
that influence those compartments in a different proportion than
occurs during the bone loss process would not result in changes
in density that conserve the relationship between DXA BMD and
biomechanical strength and fracture risk. For example, if steel
were removed proportionally from both the suspender cables
and the pillars of a bridge, the resulting decrease in strength
would not be corrected by replacing the total removed amount
of steel just to the suspender cables and not the pillars. The
relationship between DXA BMD change and fracture risk
observed with denosumab in our study may be explained by
the reported positive effect of denosumab not only on the
trabecular but also on the cortical compartment. Indeed, Seeman
et al.(21) reported differences in cortical BMD and thickness with
denosumab compared with alendronate therapy and demon-
strated that these differences impacted polar moment of inertia
estimates at the radius and tibia. In addition, changes from
baseline and from placebo at both the trabecular and the cortical
hip compartments have been reported using QCT scans from a
subset of subjects in the FREEDOM trial and these improvements
resulted in increases in estimated failure load as determined by
finite element analysis.(29,30) Altogether, these results suggest
that the distribution in bone density gains within the cortical and
trabecular compartments with denosumab treatment may be
different than the distribution achieved with other therapies and
may contribute to the different relationships observed between
BMD gains and fracture risk. Another possible explanation for the
difference between these findings and those of other therapies
could be the size of the study and the number of events
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Fig. 2. Relationship between nonvertebral fracture incidence at 36
months and percent change from baseline in total hip BMD at 36months.
Adjusted estimates for a baseline total hip BMD T-score of 2.5. Data
represent the 5th through the 95th percentiles of total hip BMD percent
change. The density curves at the bottom represent the distributions of
total hip BMD change at 36 months for each treatment group. For both
denosumab and placebo, the risk of nonvertebral fracture decreasedwith
increasing percent change in total hip BMD. The data suggest similar
relationships (slopes) for both treatment groups (interaction p
value¼ 0.38).
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observed, which allowed for a more precise estimate of the
relationship between BMD and fracture.
This study has several strengths: it involved a large number of
patients with baseline and follow-up assessments, it utilized
individual subject data, and it evaluated the relationship
between BMD changes and fracture risk using a time-dependent
analysis in addition to the standard endpoint methodological
approach previously used by others. The time-dependent
analysis had the advantage of using an estimated BMD at the
time of the actual fracture event instead of relating a change in
BMD at previous or later time points. Importantly, regardless of
the approach, the results obtained were similar.
Limitations of the study include the fact that no active
comparator data were obtained in the same trial, that the study
only enrolled untreated patients at baseline, and that only hip
BMD was measured annually in all subjects. As a result, direct
comparisons of our results to those of other studies cannot be
made, results for lumbar spine DXA BMD may differ, and it is not
known if these relationships apply to the BMD gains observed
with denosumab in subjects previously treated with alendro-
nate.(20) Additionally, the precision for the estimate of the
percent of treatment effect explained is low, leading to large
confidence intervals. Although fracture studies are powered to
detect treatment differences, they are generally underpowered
for the assessment of surrogate biomarkers in individual studies.
Furthermore, the analyses in this study included all fractures and
did not exclude fractures that occurred before the measurement
of the endpoint BMD as in previous analyses. The assessment of
change in BMD after fracture could be impacted by the loss of
mobility or increased bed rest after fracture, which could
potentially bias assessment of the relationship between changes
in BMD and fracture risk.
In summary, we found that gains in total hip BMD explain a
considerable proportion of the fracture risk reductions observed
with denosumab. Previous studies may have underestimated the
value of change in DXA BMD as a surrogate marker for the effect
of treatment on fracture risk or the relationship may be unique to
denosumab.
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